Checkpoint Inhibitors Up Survival in Early-Stage Lung Cancer

Long-awaited results from the KEYNOTE-671 and CheckMate 816 trials indicate that neoadjuvant use of immune checkpoint inhibitors can extend event-free and overall survival in patients with non-small cell lung cancer.